{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:28:17Z","timestamp":1772605697335,"version":"3.50.1"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04260-5","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T23:28:57Z","timestamp":1748388537000},"page":"325-337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pathophysiology and evaluation of bone health in adrenal diseases"],"prefix":"10.1007","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-8142","authenticated-orcid":false,"given":"M. M.","family":"Uygur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"di Filippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1308-5598","authenticated-orcid":false,"given":"S.","family":"Frara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Menotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-3398","authenticated-orcid":false,"given":"A.","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"3","key":"4260_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11154-019-09507-x","volume":"20","author":"AM Formenti","year":"2019","unstructured":"A.M. Formenti, F. Tecilazich, R. Giubbini, A. Giustina, Risk of vertebral fractures in hypoparathyroidism. Rev. Endocr. Metab. Disord. 20(3), 295\u2013302 (2019).","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"7","key":"4260_CR2","doi-asserted-by":"publisher","first-page":"e2843","DOI":"10.1210\/clinem\/dgac183","volume":"107","author":"S Frara","year":"2022","unstructured":"S. Frara, M. Melin Uygur, L. di Filippo, M. Doga, M. Losa, S. Santoro et al., High prevalence of vertebral fractures associated with preoperative GH levels in patients with recent diagnosis of acromegaly. J. Clin. Endocrinol. Metab. 107(7), e2843\u2013e2850 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"4260_CR3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s12020-016-1146-8","volume":"54","author":"G Mazziotti","year":"2016","unstructured":"G. Mazziotti, A.M. Formenti, R.A. Adler, J.P. Bilezikian, A. Grossman, E. Sbardella et al., Glucocorticoid-induced osteoporosis: pathophysiological role of GH\/IGF-I and PTH\/VITAMIN D axes, treatment options and guidelines. Endocrine 54(3), 603\u2013611 (2016).","journal-title":"Endocrine"},{"issue":"1","key":"4260_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12020-011-9486-x","volume":"40","author":"G Mazziotti","year":"2011","unstructured":"G. Mazziotti, M. Gola, A. Bianchi, T. Porcelli, A. Giampietro, V. Cimino et al., Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 40(1), 102\u2013108 (2011).","journal-title":"Endocrine"},{"issue":"2","key":"4260_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12020-017-1380-8","volume":"59","author":"V Camozzi","year":"2018","unstructured":"V. Camozzi, C. Betterle, A.C. Frigo, V. Zaccariotto, M. Zaninotto, E. De Caneva et al., Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison\u2019s disease on glucocorticoid and mineralocorticoid replacement therapy. Endocrine 59(2), 319\u2013329 (2018).","journal-title":"Endocrine"},{"issue":"3","key":"4260_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ejendo\/lvae107","volume":"191","author":"V Guarnotta","year":"2024","unstructured":"V. Guarnotta, C. Di Stefano, L. Tomasello, L. Maniscalco, G. Pizzolanti, G. Arnaldi et al., Conventional steroids vs. dual-release hydrocortisone on metabolic, cardiovascular, and bone outcomes in adrenal insufficiency: a 10-year study. Eur. J. Endocrinol. 191(3), 300\u2013311 (2024).","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"4260_CR7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1210\/jc.2007-1134","volume":"93","author":"EM Gurnell","year":"2008","unstructured":"E.M. Gurnell, P.J. Hunt, S.E. Curran, C.L. Conway, E.M. Pullenayegum, F.A. Huppert et al., Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 93(2), 400\u2013409 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"4260_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/cen.14177","volume":"92","author":"NA Ismail","year":"2020","unstructured":"N.A. Ismail, N.A. Kamaruddin, S. Azhar Shah, N. Sukor, The effect of vitamin D treatment on clinical and biochemical outcomes of primary aldosteronism. Clin. Endocrinol. 92(6), 509\u2013517 (2020).","journal-title":"Clin. Endocrinol."},{"issue":"6","key":"4260_CR9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1530\/EJE-08-0880","volume":"160","author":"K L\u00f8v\u00e5s","year":"2009","unstructured":"K. L\u00f8v\u00e5s, C.G. Gjesdal, M. Christensen, A.B. Wolff, B. Alm\u00e5s, J. Svartberg et al., Glucocorticoid replacement therapy and pharmacogenetics in Addison\u2019s disease: effects on bone. Eur. J. Endocrinol. 160(6), 993\u20131002 (2009).","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"4260_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/cen.14149","volume":"92","author":"G Riehl","year":"2020","unstructured":"G. Riehl, N. Reisch, R. Roehle, H. Claahsen van der Grinten, H. Falhammar, M. Quinkler, Bone mineral density and fractures in congenital adrenal hyperplasia: findings from the dsd-LIFE study. Clin. Endocrinol. 92(4), 284\u2013294 (2020).","journal-title":"Clin. Endocrinol."},{"issue":"5","key":"4260_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1530\/EJE-17-0417","volume":"177","author":"AS Salcuni","year":"2017","unstructured":"A.S. Salcuni, V. Carnevale, C. Battista, S. Palmieri, C. Eller-Vainicher, V. Guarnieri et al., Primary aldosteronism as a cause of secondary osteoporosis. Eur. J. Endocrinol. 177(5), 431\u2013437 (2017).","journal-title":"Eur. J. Endocrinol."},{"key":"4260_CR12","doi-asserted-by":"publisher","first-page":"115221","DOI":"10.1016\/j.bone.2020.115221","volume":"133","author":"M Yokomoto-Umakoshi","year":"2020","unstructured":"M. Yokomoto-Umakoshi, H. Umakoshi, T. Fukumoto, Y. Matsuda, H. Nagata, M. Ogata et al., Pheochromocytoma and paraganglioma: an emerging cause of secondary osteoporosis. Bone 133, 115221 (2020).","journal-title":"Bone"},{"issue":"2","key":"4260_CR13","doi-asserted-by":"publisher","first-page":"e475","DOI":"10.1210\/clinem\/dgab712","volume":"107","author":"H Falhammar","year":"2021","unstructured":"H. Falhammar, L. Fris\u00e9n, A.L. Hirschberg, A. Nordenskj\u00f6ld, C. Almqvist, A. Nordenstr\u00f6m, Increased prevalence of fractures in congenital adrenal hyperplasia: a swedish population-based national cohort study. J. Clin. Endocrinol. Metab. 107(2), e475\u2013e486 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"4260_CR14","doi-asserted-by":"publisher","first-page":"101515","DOI":"10.1016\/j.beem.2021.101515","volume":"35","author":"S Frara","year":"2021","unstructured":"S. Frara, A. Allora, L. di Filippo, A.M. Formenti, P. Loli, E. Polizzi et al., Osteopathy in mild adrenal Cushing\u2019s syndrome and cushing disease. Best. Pract. Res. Clin. Endocrinol. Metab. 35(2), 101515 (2021).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"issue":"2","key":"4260_CR15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1210\/jc.2017-02043","volume":"103","author":"BJ Kim","year":"2018","unstructured":"B.J. Kim, M.K. Kwak, S.H. Ahn, H. Kim, S.H. Lee, J.M. Koh, Lower trabecular bone score in patients with primary aldosteronism: human skeletal deterioration by aldosterone excess. J. Clin. Endocrinol. Metab. 103(2), 615\u2013621 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"4260_CR16","doi-asserted-by":"publisher","first-page":"R231","DOI":"10.1530\/EJE-17-0154","volume":"177","author":"G Mazziotti","year":"2017","unstructured":"G. Mazziotti, A.M. Formenti, S. Frara, E. Roca, P. Mortini, A. Berruti et al., Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. Eur. J. Endocrinol. 177(5), R231\u2013R248 (2017).","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"4260_CR17","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1210\/jc.2016-3206","volume":"102","author":"M Notsu","year":"2017","unstructured":"M. Notsu, M. Yamauchi, M. Yamamoto, K. Nawata, T. Sugimoto, Primary aldosteronism as a risk factor for vertebral fracture. J. Clin. Endocrinol. Metab. 102(4), 1237\u20131243 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"4260_CR18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s40618-023-02198-x","volume":"47","author":"W Qi","year":"2024","unstructured":"W. Qi, L. Cui, R. Jiajue, Q. Pang, Y. Chi, W. Liu et al., Deteriorated bone microarchitecture caused by sympathetic overstimulation in pheochromocytoma and paraganglioma. J. Endocrinol. Invest. 47(4), 843\u2013856 (2024).","journal-title":"J. Endocrinol. Invest."},{"issue":"2","key":"4260_CR19","doi-asserted-by":"publisher","first-page":"e602","DOI":"10.1210\/clinem\/dgaa738","volume":"106","author":"L di Filippo","year":"2021","unstructured":"L. di Filippo, A.M. Formenti, M. Doga, E. Pedone, P. Rovere-Querini, A. Giustina, Radiological thoracic vertebral fractures are highly prevalent in COVID-19 and predict disease outcomes. J. Clin. Endocrinol. Metab. 106(2), e602\u2013e614 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"4260_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.tem.2023.01.006","volume":"34","author":"MM Uygur","year":"2023","unstructured":"M.M. Uygur, S. Frara, L. di Filippo, A. Giustina, New tools for bone health assessment in secreting pituitary adenomas. Trends Endocrinol. Metab. 34(4), 231\u2013242 (2023).","journal-title":"Trends Endocrinol. Metab."},{"key":"4260_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2018.06.023","volume":"116","author":"BJ Kim","year":"2018","unstructured":"B.J. Kim, M.K. Kwak, J.S. Kim, S.H. Lee, J.M. Koh, Higher sympathetic activity as a risk factor for skeletal deterioration in pheochromocytoma. Bone 116, 1\u20137 (2018).","journal-title":"Bone"},{"issue":"2","key":"4260_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s12020-024-03709-3","volume":"84","author":"K Furman","year":"2024","unstructured":"K. Furman, P. Gut, A. Sowi\u0144ska, M. Rucha\u0142a, M. Fichna, Predictors of bone mineral density in patients receiving glucocorticoid replacement for Addison\u2019s disease. Endocrine 84(2), 711\u2013719 (2024).","journal-title":"Endocrine"},{"issue":"5","key":"4260_CR23","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/cen.14809","volume":"99","author":"P Wiromrat","year":"2023","unstructured":"P. Wiromrat, P. Namphaisan, N. Wongsurawat, O. Panamonta, N. Nasomyont, Elevated bone turnover markers predict bone mineral density accrual in adolescents with 21-hydroxylase deficiency. Clin. Endocrinol. 99(5), 462\u2013469 (2023).","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"4260_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1055\/s-0031-1295438","volume":"44","author":"A Hannemann","year":"2012","unstructured":"A. Hannemann, H. Wallaschofski, Prevalence of primary aldosteronism in patient\u2019s cohorts and in population-based studies\u2013a review of the current literature. Horm. Metab. Res. 44(3), 157\u2013162 (2012).","journal-title":"Horm. Metab. Res."},{"issue":"5","key":"4260_CR25","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata et al., The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101(5), 1889\u20131916 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"4260_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/joim.12831","volume":"285","author":"WF Young Jr.","year":"2019","unstructured":"W.F. Young Jr., Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J. Intern. Med. 285(2), 126\u2013148 (2019).","journal-title":"J. Intern. Med."},{"issue":"10","key":"4260_CR27","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/jbmr.1660","volume":"27","author":"AS Salcuni","year":"2012","unstructured":"A.S. Salcuni, S. Palmieri, V. Carnevale, V. Morelli, C. Battista, V. Guarnieri et al., Bone involvement in aldosteronism. J. Bone Miner. Res. 27(10), 2217\u20132222 (2012).","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"4260_CR28","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1007\/s00198-013-2399-1","volume":"24","author":"L Ceccoli","year":"2013","unstructured":"L. Ceccoli, V. Ronconi, L. Giovannini, M. Marcheggiani, F. Turchi, M. Boscaro et al., Bone health and aldosterone excess. Osteoporos. Int. 24(11), 2801\u20132807 (2013).","journal-title":"Osteoporos. Int."},{"issue":"7","key":"4260_CR29","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/jch.12822","volume":"18","author":"D Armanini","year":"2016","unstructured":"D. Armanini, A. Andrisani, G. Ambrosini, G. Don\u00e0, V. Camozzi, L. Bordin et al., Interrelationship between Vitamin D insufficiency, calcium homeostasis, hyperaldosteronism, and autoimmunity. J. Clin. Hypertens. 18(7), 614\u2013616 (2016).","journal-title":"J. Clin. Hypertens."},{"key":"4260_CR30","doi-asserted-by":"publisher","first-page":"836529","DOI":"10.1155\/2014\/836529","volume":"2014","author":"L Petramala","year":"2014","unstructured":"L. Petramala, L. Zinnamosca, A. Settevendemmie, C. Marinelli, M. Nardi, A. Concistr\u00e8 et al., Bone and mineral metabolism in patients with primary aldosteronism. Int. J. Endocrinol. 2014, 836529 (2014).","journal-title":"Int. J. Endocrinol."},{"issue":"2","key":"4260_CR31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/HYPERTENSIONAHA.112.195891","volume":"60","author":"GP Rossi","year":"2012","unstructured":"G.P. Rossi, F. Ragazzo, T.M. Seccia, C. Maniero, M. Barisa, L.A. Cal\u00f2 et al., Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension 60(2), 431\u2013436 (2012).","journal-title":"Hypertension"},{"issue":"5","key":"4260_CR32","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ki.1991.123","volume":"39","author":"J Lemann Jr.","year":"1991","unstructured":"J. Lemann Jr., J.A. Pleuss, R.W. Gray, R.G. Hoffmann, Potassium administration reduces and potassium deprivation increases urinary calcium excretion in healthy adults [corrected]. Kidney Int. 39(5), 973\u2013983 (1991).","journal-title":"Kidney Int."},{"key":"4260_CR33","doi-asserted-by":"publisher","first-page":"1373862","DOI":"10.3389\/fendo.2024.1373862","volume":"15","author":"S Song","year":"2024","unstructured":"S. Song, X. Cai, J. Hu, Q. Zhu, D. Shen, M. Heizhati et al., Correlation between plasma aldosterone concentration and bone mineral density in middle-aged and elderly hypertensive patients: potential impact on osteoporosis and future fracture risk. Front. Endocrinol. 15, 1373862 (2024).","journal-title":"Front. Endocrinol."},{"key":"4260_CR34","doi-asserted-by":"publisher","first-page":"1124646","DOI":"10.3389\/fendo.2023.1124646","volume":"14","author":"P Kober","year":"2023","unstructured":"P. Kober, N. Rusetska, B.J. Mossakowska, M. Maksymowicz, M. P\u0119kul, G. Zieli\u0144ski et al., The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing\u2019s disease and silent corticotroph tumors. Front. Endocrinol. 14, 1124646 (2023).","journal-title":"Front. Endocrinol."},{"issue":"7","key":"4260_CR35","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1161\/01.CIR.0000155621.10213.06","volume":"111","author":"VS Chhokar","year":"2005","unstructured":"V.S. Chhokar, Y. Sun, S.K. Bhattacharya, R.A. Ahokas, L.K. Myers, Z. Xing et al., Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 111(7), 871\u2013878 (2005).","journal-title":"Circulation"},{"key":"4260_CR36","doi-asserted-by":"publisher","first-page":"105434","DOI":"10.1016\/j.jsbmb.2019.105434","volume":"193","author":"X Gao","year":"2019","unstructured":"X. Gao, Y. Yamazaki, Y. Tezuka, Y. Onodera, H. Ogata, K. Omata et al., The crosstalk between aldosterone and calcium metabolism in primary aldosteronism: a possible calcium metabolism-associated aberrant \u201cneoplastic\u201d steroidogenesis in adrenals. J. Steroid Biochem. Mol. Biol. 193, 105434 (2019).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"8","key":"4260_CR37","doi-asserted-by":"publisher","first-page":"e93136","DOI":"10.1172\/jci.insight.93136","volume":"2","author":"W Arlt","year":"2017","unstructured":"W. Arlt, K. Lang, A.J. Sitch, A.S. Dietz, Y. Rhayem, I. Bancos et al., Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight 2(8), e93136 (2017).","journal-title":"JCI Insight"},{"issue":"4","key":"4260_CR38","first-page":"387","volume":"44","author":"HH Loh","year":"2019","unstructured":"H.H. Loh, A. Yee, H.S. Loh, Bone health among patients with primary aldosteronism: a systematic review and meta-analysis. Minerva Endocrinol. 44(4), 387\u2013396 (2019).","journal-title":"Minerva Endocrinol."},{"issue":"3","key":"4260_CR39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s12020-020-02348-8","volume":"69","author":"C Adolf","year":"2020","unstructured":"C. Adolf, L.T. Braun, C.T. Fuss, S. Hahner, H. K\u00fcnzel, L. Handgriff et al., Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism. Endocrine 69(3), 625\u2013633 (2020).","journal-title":"Endocrine"},{"issue":"3","key":"4260_CR40","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/cen.14145","volume":"92","author":"M Yokomoto-Umakoshi","year":"2020","unstructured":"M. Yokomoto-Umakoshi, R. Sakamoto, H. Umakoshi, Y. Matsuda, H. Nagata, T. Fukumoto et al., Unilateral primary aldosteronism as an independent risk factor for vertebral fracture. Clin. Endocrinol. 92(3), 206\u2013213 (2020).","journal-title":"Clin. Endocrinol."},{"issue":"4","key":"4260_CR41","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/jbmr.3033","volume":"32","author":"VC Wu","year":"2017","unstructured":"V.C. Wu, C.H. Chang, C.Y. Wang, Y.H. Lin, T.W. Kao, P.C. Lin et al., Risk of fracture in primary aldosteronism: a population-based cohort study. J. Bone Min. Res. 32(4), 743\u2013752 (2017).","journal-title":"J. Bone Min. Res."},{"issue":"2","key":"4260_CR42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jacc.2008.03.039","volume":"52","author":"LD Carbone","year":"2008","unstructured":"L.D. Carbone, J.D. Cross, S.H. Raza, A.J. Bush, R.J. Sepanski, S. Dhawan et al., Fracture risk in men with congestive heart failure: risk reduction with spironolactone. J. Am. Coll. Cardiol. 52(2), 135\u2013138 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"4260_CR43","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00198-024-07132-2","volume":"35","author":"E Gkaniatsa","year":"2024","unstructured":"E. Gkaniatsa, T.Z. Sandstr\u00f6m, A. Rosengren, P. Trimpou, A. Muth, G. Johannsson et al., Hip fractures in patients with primary aldosteronism - a swedish nationwide study. Osteoporos. Int. 35(9), 1585\u20131593 (2024).","journal-title":"Osteoporos. Int."},{"key":"4260_CR44","doi-asserted-by":"publisher","first-page":"884302","DOI":"10.3389\/fendo.2022.884302","volume":"13","author":"X Lv","year":"2022","unstructured":"X. Lv, H. Hu, C. Shen, X. Zhang, L. Yan, S. Zhang et al., Risk factors associated with lower bone mineral density in primary aldosteronism patients. Front. Endocrinol. 13, 884302 (2022).","journal-title":"Front. Endocrinol."},{"issue":"7","key":"4260_CR45","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41371-018-0069-7","volume":"32","author":"X Shu","year":"2018","unstructured":"X. Shu, M. Mei, L. Ma, Z. Wang, S. Yang, J. Hu et al., Postmenopausal osteoporosis is associated with elevated aldosterone\/renin ratio. J. Hum. Hypertens. 32(7), 524\u2013530 (2018).","journal-title":"J. Hum. Hypertens."},{"issue":"1","key":"4260_CR46","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12018-019-9257-4","volume":"17","author":"B-J Kim","year":"2019","unstructured":"B.-J. Kim, S.H. Lee, J.-M. Koh, Effects of sympathetic activity on human skeletal homeostasis: clinical evidence from pheochromocytoma. Clin. Rev. Bone Miner. Metab. 17(1), 40\u201347 (2019).","journal-title":"Clin. Rev. Bone Miner. Metab."},{"issue":"34","key":"4260_CR47","doi-asserted-by":"publisher","first-page":"30192","DOI":"10.1074\/jbc.M504179200","volume":"280","author":"H Kondo","year":"2005","unstructured":"H. Kondo, A. Nifuji, S. Takeda, Y. Ezura, S.R. Rittling, D.T. Denhardt et al., Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J. Biol. Chem. 280(34), 30192\u201330200 (2005).","journal-title":"J. Biol. Chem."},{"issue":"45","key":"4260_CR48","doi-asserted-by":"publisher","first-page":"16876","DOI":"10.1073\/pnas.0604234103","volume":"103","author":"R Yirmiya","year":"2006","unstructured":"R. Yirmiya, I. Goshen, A. Bajayo, T. Kreisel, S. Feldman, J. Tam et al., Depression induces bone loss through stimulation of the sympathetic nervous system. Proc. Natl. Acad. Sci. USA 103(45), 16876\u201316881 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"4260_CR49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00223-010-9421-9","volume":"88","author":"H Kondo","year":"2011","unstructured":"H. Kondo, A. Togari, Continuous treatment with a low-dose \u03b2-agonist reduces bone mass by increasing bone resorption without suppressing bone formation. Calcif. Tissue Int. 88(1), 23\u201332 (2011).","journal-title":"Calcif. Tissue Int."},{"issue":"5","key":"4260_CR50","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.bone.2005.07.012","volume":"37","author":"N Bonnet","year":"2005","unstructured":"N. Bonnet, C.L. Benhamou, B. Brunet-Imbault, A. Arlettaz, M.N. Horcajada, O. Richard et al., Severe bone alterations under beta2 agonist treatments: bone mass, microarchitecture and strength analyses in female rats. Bone 37(5), 622\u2013633 (2005).","journal-title":"Bone"},{"issue":"2","key":"4260_CR51","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cell.2007.05.038","volume":"130","author":"L Yan","year":"2007","unstructured":"L. Yan, D.E. Vatner, J.P. O\u2019Connor, A. Ivessa, H. Ge, W. Chen et al., Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 130(2), 247\u2013258 (2007).","journal-title":"Cell"},{"issue":"4","key":"4260_CR52","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1084\/jem.20102608","volume":"208","author":"D Kajimura","year":"2011","unstructured":"D. Kajimura, E. Hinoi, M. Ferron, A. Kode, K.J. Riley, B. Zhou et al., Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual. J. Exp. Med. 208(4), 841\u2013851 (2011).","journal-title":"J. Exp. Med."},{"issue":"3","key":"4260_CR53","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0092-8674(04)00344-7","volume":"117","author":"X Yang","year":"2004","unstructured":"X. Yang, K. Matsuda, P. Bialek, S. Jacquot, H.C. Masuoka, T. Schinke et al., ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for coffin-lowry syndrome. Cell 117(3), 387\u2013398 (2004).","journal-title":"Cell"},{"issue":"2","key":"4260_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00223-006-0213-1","volume":"80","author":"F de Vries","year":"2007","unstructured":"F. de Vries, P.C. Souverein, C. Cooper, H.G. Leufkens, T.P. van Staa, Use of beta-blockers and the risk of hip\/femur fracture in the United Kingdom and The Netherlands. Calcif. Tissue Int. 80(2), 69\u201375 (2007).","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"4260_CR55","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archinte.166.2.241","volume":"166","author":"BF Gage","year":"2006","unstructured":"B.F. Gage, E. Birman-Deych, M.J. Radford, D.S. Nilasena, E.F. Binder, Risk of osteoporotic fracture in elderly patients taking warfarin: results from the national registry of atrial fibrillation 2. Arch. Intern. Med. 166(2), 241\u2013246 (2006).","journal-title":"Arch. Intern. Med."},{"issue":"9","key":"4260_CR56","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00198-007-0354-8","volume":"18","author":"C Meisinger","year":"2007","unstructured":"C. Meisinger, M. Heier, O. Lang, A. D\u00f6ring, Beta-blocker use and risk of fractures in men and women from the general population: the MONICA\/KORA Augsburg cohort study. Osteoporos. Int. 18(9), 1189\u20131195 (2007).","journal-title":"Osteoporos. Int."},{"issue":"11","key":"4260_CR57","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/jama.292.11.1326","volume":"292","author":"RG Schlienger","year":"2004","unstructured":"R.G. Schlienger, M.E. Kraenzlin, S.S. Jick, C.R. Meier, Use of beta-blockers and risk of fractures. Jama 292(11), 1326\u20131332 (2004).","journal-title":"Jama"},{"issue":"1","key":"4260_CR58","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00198-013-2498-z","volume":"25","author":"KA Toulis","year":"2014","unstructured":"K.A. Toulis, K. Hemming, S. Stergianos, K. Nirantharakumar, J.P. Bilezikian, \u03b2-adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects. Osteoporos. Int. 25(1), 121\u2013129 (2014).","journal-title":"Osteoporos. Int."},{"issue":"2","key":"4260_CR59","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/BF03654781","volume":"23","author":"M Sosa","year":"2011","unstructured":"M. Sosa, P. Saavedra, M.J. G\u00f3mez de Tejada, J. Mosquera, R. P\u00e9rez-Cano, J.M. Olmos et al., Beta-blocker use is associated with fragility fractures in postmenopausal women with coronary heart disease. Aging Clin. Exp. Res. 23(2), 112\u2013117 (2011).","journal-title":"Aging Clin. Exp. Res."},{"issue":"4","key":"4260_CR60","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1359\/JBMR.041202","volume":"20","author":"IR Reid","year":"2005","unstructured":"I.R. Reid, G.D. Gamble, A.B. Grey, D.M. Black, K.E. Ensrud, W.S. Browner et al., beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J. Bone Min. Res. 20(4), 613\u2013618 (2005).","journal-title":"J. Bone Min. Res."},{"issue":"3","key":"4260_CR61","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1532-5415.2005.53178_7.x","volume":"53","author":"R Levasseur","year":"2005","unstructured":"R. Levasseur, P. Dargent-Molina, J.P. Sabatier, C. Marcelli, G. Br\u00e9art, Beta-blocker use, bone mineral density, and fracture risk in older women: results from the epidemiologie de l\u2019Osteoporose prospective study. J. Am. Geriatr. Soc. 53(3), 550\u2013552 (2005).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"11","key":"4260_CR62","doi-asserted-by":"publisher","first-page":"E2093","DOI":"10.1210\/jc.2012-2823","volume":"97","author":"AG Veldhuis-Vlug","year":"2012","unstructured":"A.G. Veldhuis-Vlug, M. El Mahdiui, E. Endert, A.C. Heijboer, E. Fliers, P.H. Bisschop, Bone resorption is increased in pheochromocytoma patients and normalizes following adrenalectomy. J. Clin. Endocrinol. Metab. 97(11), E2093\u2013E2097 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"4260_CR63","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1210\/jc.2017-00169","volume":"102","author":"BJ Kim","year":"2017","unstructured":"B.J. Kim, M.K. Kwak, S.H. Ahn, H. Kim, S.H. Lee, K.H. Song et al., Lower bone mass and higher bone resorption in pheochromocytoma: importance of sympathetic activity on human bone. J. Clin. Endocrinol. Metab. 102(8), 2711\u20132718 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4260_CR64","doi-asserted-by":"publisher","first-page":"115607","DOI":"10.1016\/j.bone.2020.115607","volume":"142","author":"M Yokomoto-Umakoshi","year":"2021","unstructured":"M. Yokomoto-Umakoshi, H. Umakoshi, R. Sakamoto, T. Fukumoto, M. Ogata, Y. Nakano et al., Role of deteriorated bone quality in the development of osteoporosis in pheochromocytoma and paraganglioma. Bone 142, 115607 (2021).","journal-title":"Bone"},{"issue":"1","key":"4260_CR65","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/ijem.ijem_322_22","volume":"27","author":"S Khatiwada","year":"2023","unstructured":"S. Khatiwada, S. Agarwal, D. Kandasamy, R. Kumar, V.P. Jyotsna, N. Tandon, Prevalence and Predictors of osteoporosis\/BMD below expected range for age in pheochromocytoma\/paraganglioma and BMD, TBS change post-operatively: a prospective cohort study. Indian. J. Endocrinol. Metab. 27(1), 87\u201390 (2023).","journal-title":"Indian. J. Endocrinol. Metab."},{"issue":"11","key":"4260_CR66","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s00198-020-05527-5","volume":"31","author":"M Yokomoto-Umakoshi","year":"2020","unstructured":"M. Yokomoto-Umakoshi, H. Umakoshi, M. Ogata, T. Fukumoto, Y. Matsuda, T. Miyazawa et al., Coexistence of osteoporosis and atherosclerosis in pheochromocytoma: new insights into its long-term management. Osteoporos. Int. 31(11), 2151\u20132160 (2020).","journal-title":"Osteoporos. Int."},{"issue":"6","key":"4260_CR67","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1210\/endrev\/bnaa008","volume":"41","author":"M Sherlock","year":"2020","unstructured":"M. Sherlock, A. Scarsbrook, A. Abbas, S. Fraser, P. Limumpornpetch, R. Dineen et al., Adrenal incidentaloma. Endocr. Rev. 41(6), 775\u2013820 (2020).","journal-title":"Endocr. Rev."},{"issue":"16","key":"4260_CR68","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1056\/NEJMcp2031112","volume":"384","author":"E Kebebew","year":"2021","unstructured":"E. Kebebew, Adrenal incidentaloma. N. Engl. J. Med. 384(16), 1542\u20131551 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"4260_CR69","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","volume":"189","author":"M Fassnacht","year":"2023","unstructured":"M. Fassnacht, S. Tsagarakis, M. Terzolo, A. Tabarin, A. Sahdev, J. Newell-Price et al., European society of endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European network for the study of adrenal tumors. Eur. J. Endocrinol. 189(1), G1\u2013g42 (2023).","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"4260_CR70","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S2213-8587(20)30314-4","volume":"8","author":"A Ebbehoj","year":"2020","unstructured":"A. Ebbehoj, D. Li, R.J. Kaur, C. Zhang, S. Singh, T. Li et al., Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study. Lancet Diabetes Endocrinol. 8(11), 894\u2013902 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"4260_CR71","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1055\/a-1827-4113","volume":"130","author":"A Czapla-Iskrzycka","year":"2022","unstructured":"A. Czapla-Iskrzycka, R. Swiatkowska-Stodulska, K. Sworczak, Comorbidities in mild autonomous cortisol secretion - a clinical review of literature. Exp. Clin. Endocrinol. Diabetes 130(9), 567\u2013576 (2022).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"10","key":"4260_CR72","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"E. Canalis, G. Mazziotti, A. Giustina, J.P. Bilezikian, Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18(10), 1319\u20131328 (2007).","journal-title":"Osteoporos. Int."},{"issue":"1","key":"4260_CR73","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1210\/jcem-68-1-120","volume":"68","author":"A Giustina","year":"1989","unstructured":"A. Giustina, G. Romanelli, R. Candrina, G. Giustina, Growth hormone deficiency in patients with idiopathic adrenocorticotropin deficiency resolves during glucocorticoid replacement. J. Clin. Endocrinol. Metab. 68(1), 120\u2013124 (1989).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4260_CR74","first-page":"122","volume":"80","author":"A Giustina","year":"1995","unstructured":"A. Giustina, A.R. Bussi, C. Jacobello, W.B. Wehrenberg, Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J. Clin. Endocrinol. Metab. 80(1), 122\u2013129 (1995).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"4260_CR75","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s11102-022-01252-w","volume":"25","author":"S Frara","year":"2022","unstructured":"S. Frara, L. di Filippo, M. Doga, P. Loli, F.F. Casanueva, A. Giustina, Novel approaches to bone comorbidity in Cushing\u2019s disease: an update. Pituitary 25(5), 754\u2013759 (2022).","journal-title":"Pituitary"},{"issue":"2","key":"4260_CR76","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1530\/eje.1.01841","volume":"152","author":"S Bonadonna","year":"2005","unstructured":"S. Bonadonna, A. Burattin, M. Nuzzo, G. Bugari, E.A. Rosei, D. Valle et al., Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur. J. Endocrinol. 152(2), 199\u2013205 (2005).","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"4260_CR77","doi-asserted-by":"publisher","first-page":"bvaf008","DOI":"10.1210\/jendso\/bvaf008","volume":"9","author":"G Voltan","year":"2025","unstructured":"G. Voltan, P. Mazzeo, M. Cannito, S. Pinelli, M. Barbot, C. Scaroni et al., Relationship among fragility fractures and the overall cardiovascular burden in endogenous cushing syndrome. J. Endocr. Soc. 9(3), bvaf008 (2025).","journal-title":"J. Endocr. Soc."},{"issue":"1-2","key":"4260_CR78","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.steroids.2010.08.007","volume":"76","author":"M Sereg","year":"2011","unstructured":"M. Sereg, J. Toke, A. Patocs, I. Varga, P. Igaz, N. Szucs et al., Diagnostic performance of salivary cortisol and serum osteocalcin measurements in patients with overt and subclinical Cushing\u2019s syndrome. Steroids 76(1-2), 38\u201342 (2011).","journal-title":"Steroids"},{"issue":"5","key":"4260_CR79","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1210\/clinem\/dgaa120","volume":"105","author":"S Athimulam","year":"2020","unstructured":"S. Athimulam, D. Delivanis, M. Thomas, W.F. Young, S. Khosla, M.T. Drake et al., The impact of mild autonomous cortisol secretion on bone turnover markers. J. Clin. Endocrinol. Metab. 105(5), 1469\u20131477 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"4260_CR80","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/SLA.0b013e31819a47d2","volume":"249","author":"A Toniato","year":"2009","unstructured":"A. Toniato, I. Merante-Boschin, G. Opocher, M.R. Pelizzo, F. Schiavi, E. Ballotta, Surgical versus conservative management for subclinical cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann. Surg. 249(3), 388\u2013391 (2009).","journal-title":"Ann. Surg."},{"issue":"2","key":"4260_CR81","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1210\/jcem.86.2.7178","volume":"86","author":"G Osella","year":"2001","unstructured":"G. Osella, G. Reimondo, P. Peretti, A. Ali, P. Paccotti, A. Angeli et al., The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis. J. Clin. Endocrinol. Metab. 86(2), 604\u2013607 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"4260_CR82","first-page":"1440","volume":"85","author":"R Rossi","year":"2000","unstructured":"R. Rossi, L. Tauchmanova, A. Luciano, M. Di Martino, C. Battista, L. Del Viscovo et al., Subclinical Cushing\u2019s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J. Clin. Endocrinol. Metab. 85(4), 1440\u20131448 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"4260_CR83","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1210\/jcem.84.7.5856","volume":"84","author":"M Torlontano","year":"1999","unstructured":"M. Torlontano, I. Chiodini, M. Pileri, G. Guglielmi, M. Cammisa, S. Modoni et al., Altered bone mass and turnover in female patients with adrenal incidentaloma: the effect of subclinical hypercortisolism. J. Clin. Endocrinol. Metab. 84(7), 2381\u20132385 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"4260_CR84","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1210\/jc.2003-031413","volume":"89","author":"I Chiodini","year":"2004","unstructured":"I. Chiodini, G. Guglielmi, C. Battista, V. Carnevale, M. Torlontano, M. Cammisa et al., Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effects of subclinical hypercortisolism and gonadal status. J. Clin. Endocrinol. Metab. 89(5), 2237\u20132241 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"4260_CR85","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1210\/jc.2009-0468","volume":"94","author":"I Chiodini","year":"2009","unstructured":"I. Chiodini, V. Morelli, B. Masserini, A.S. Salcuni, C. Eller-Vainicher, R. Viti et al., Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J. Clin. Endocrinol. Metab. 94(9), 3207\u20133214 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"4260_CR86","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1365-2265.2008.03310.x","volume":"70","author":"I Chiodini","year":"2009","unstructured":"I. Chiodini, R. Viti, F. Coletti, G. Guglielmi, C. Battista, F. Ermetici et al., Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures. Clin. Endocrinol. 70(2), 208\u2013213 (2009).","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"4260_CR87","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1530\/EJE-07-0137","volume":"157","author":"L Tauchmanova","year":"2007","unstructured":"L. Tauchmanova, R. Pivonello, M.C. De Martino, A. Rusciano, M. De Leo, C. Ruosi et al., Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. Eur. J. Endocrinol. 157(3), 359\u2013366 (2007).","journal-title":"Eur. J. Endocrinol."},{"issue":"7","key":"4260_CR88","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/jbmr\/zjae067","volume":"39","author":"R Pal","year":"2024","unstructured":"R. Pal, M. Banerjee, T.N. Prasad, R. Walia, T. Bhadada, J. Singh et al., Fracture risk and bone health in adrenal adenomas with mild autonomous cortisol secretion\/subclinical hypercortisolism: a systematic review, meta-analysis and meta-regression. J. Bone Min. Res. 39(7), 885\u2013897 (2024).","journal-title":"J. Bone Min. Res."},{"issue":"3","key":"4260_CR89","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1530\/EJE-15-0977","volume":"174","author":"AS Salcuni","year":"2016","unstructured":"A.S. Salcuni, V. Morelli, C. Eller Vainicher, S. Palmieri, E. Cairoli, A. Spada et al., Adrenalectomy reduces the risk of vertebral fractures in patients with monolateral adrenal incidentalomas and subclinical hypercortisolism. Eur. J. Endocrinol. 174(3), 261\u2013269 (2016).","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"4260_CR90","doi-asserted-by":"publisher","first-page":"e623","DOI":"10.1210\/clinem\/dgad560","volume":"109","author":"V Favero","year":"2024","unstructured":"V. Favero, C. Eller-Vainicher, V. Morelli, E. Cairoli, A.S. Salcuni, A. Scillitani et al., Increased risk of vertebral fractures in patients with mild autonomous cortisol secretion. J. Clin. Endocrinol. Metab. 109(2), e623\u2013e632 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"4260_CR91","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/ejendo\/lvad038","volume":"188","author":"G Zavatta","year":"2023","unstructured":"G. Zavatta, V. Vicennati, P. Altieri, L. Tucci, G. Colombin, K. Coscia et al., Mild autonomous cortisol secretion in adrenal incidentalomas and risk of fragility fractures: a large cross-sectional study. Eur. J. Endocrinol. 188(4), 343\u2013352 (2023).","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"4260_CR92","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/jbmr.1648","volume":"27","author":"C Eller-Vainicher","year":"2012","unstructured":"C. Eller-Vainicher, V. Morelli, F.M. Ulivieri, S. Palmieri, V.V. Zhukouskaya, E. Cairoli et al., Bone quality, as measured by trabecular bone score in patients with adrenal incidentalomas with and without subclinical hypercortisolism. J. Bone Min. Res. 27(10), 2223\u20132230 (2012).","journal-title":"J. Bone Min. Res."},{"issue":"2","key":"4260_CR93","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/cen.13743","volume":"89","author":"H Vinolas","year":"2018","unstructured":"H. Vinolas, V. Grouthier, N. Mehsen-Cetre, A. Boisson, R. Winzenrieth, T. Schaeverbeke et al., Assessment of vertebral microarchitecture in overt and mild Cushing\u2019s syndrome using trabecular bone score. Clin. Endocrinol. 89(2), 148\u2013154 (2018).","journal-title":"Clin. Endocrinol."},{"issue":"8","key":"4260_CR94","doi-asserted-by":"publisher","first-page":"dgaa263","DOI":"10.1210\/clinem\/dgaa263","volume":"105","author":"AB Moraes","year":"2020","unstructured":"A.B. Moraes, M.P. de Paula, F. de Paula Paranhos-Neto, E.M.R. Cavalari, F.F.C. de Morais, D.S.C. Curi et al., Bone evaluation by high-resolution peripheral quantitative computed tomography in patients with adrenal incidentaloma. J. Clin. Endocrinol. Metab. 105(8), dgaa263 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"4260_CR95","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"S.R. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Don-Wauchope, G.D. Hammer et al., Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101(2), 364\u2013389 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4260_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13506-5","volume":"12","author":"V Guarnotta","year":"2022","unstructured":"V. Guarnotta, C. Di Stefano, C. Giordano, Long-term outcomes of conventional and novel steroid replacement therapy on bone health in primary adrenal insufficiency. Sci. Rep. 12(1), 13280 (2022).","journal-title":"Sci. Rep."},{"issue":"1","key":"4260_CR97","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1210\/jcem-72-1-39","volume":"72","author":"NV Esteban","year":"1991","unstructured":"N.V. Esteban, T. Loughlin, A.L. Yergey, J.K. Zawadzki, J.D. Booth, J.C. Winterer et al., Daily cortisol production rate in man determined by stable isotope dilution\/mass spectrometry. J. Clin. Endocrinol. Metab. 72(1), 39\u201345 (1991).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4260_CR98","doi-asserted-by":"publisher","first-page":"1234237","DOI":"10.3389\/fendo.2023.1234237","volume":"14","author":"F Bioletto","year":"2023","unstructured":"F. Bioletto, M. Barale, M. Parasiliti-Caprino, J. Giannelli, L. Campioni, V. Cappiello et al., Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency. Front. Endocrinol. 14, 1234237 (2023).","journal-title":"Front. Endocrinol."},{"issue":"1","key":"4260_CR99","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12020-021-02723-z","volume":"74","author":"L Li","year":"2021","unstructured":"L. Li, S. Bensing, H. Falhammar, Rate of fracture in patients with glucocorticoid replacement therapy: a systematic review and meta-analysis. Endocrine 74(1), 29\u201337 (2021).","journal-title":"Endocrine"},{"issue":"1","key":"4260_CR100","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.bone.2013.08.016","volume":"57","author":"L Gifre","year":"2013","unstructured":"L. Gifre, S. Ruiz-Gasp\u00e0, A. Monegal, B. Nomdedeu, X. Filella, N. Gua\u00f1abens et al., Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 57(1), 272\u2013276 (2013).","journal-title":"Bone"},{"issue":"10","key":"4260_CR101","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/jbmr.2869","volume":"31","author":"AY Sato","year":"2016","unstructured":"A.Y. Sato, M. Cregor, J. Delgado-Calle, K.W. Condon, M.R. Allen, M. Peacock et al., Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of sost\/sclerostin. J. Bone Min. Res. 31(10), 1791\u20131802 (2016).","journal-title":"J. Bone Min. Res."},{"issue":"1","key":"4260_CR102","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00198-015-3308-6","volume":"27","author":"W Yao","year":"2016","unstructured":"W. Yao, W. Dai, L. Jiang, E.Y. Lay, Z. Zhong, R.O. Ritchie et al., Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporos. Int. 27(1), 283\u2013294 (2016).","journal-title":"Osteoporos. Int."},{"issue":"3","key":"4260_CR103","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s12020-021-02751-9","volume":"73","author":"MM Uygur","year":"2021","unstructured":"M.M. Uygur, D.D. Yaz\u0131c\u0131, O. Bu\u011fdayc\u0131, D.G. Yavuz, Prevalence of vertebral fractures and serum sclerostin levels in acromegaly. Endocrine 73(3), 667\u2013673 (2021).","journal-title":"Endocrine"},{"key":"4260_CR104","doi-asserted-by":"publisher","first-page":"996157","DOI":"10.3389\/fendo.2022.996157","volume":"13","author":"A Zdrojowy-We\u0142na","year":"2022","unstructured":"A. Zdrojowy-We\u0142na, J. Halupczok-\u017by\u0142a, N. S\u0142oka, J. Syrycka, Gojny \u0141, M. Bolanowski, Trabecular bone score and sclerostin concentrations in patients with primary adrenal insufficiency. Front. Endocrinol. 13, 996157 (2022).","journal-title":"Front. Endocrinol."},{"issue":"1","key":"4260_CR105","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1210\/jc.2011-2036","volume":"97","author":"KR Koetz","year":"2012","unstructured":"K.R. Koetz, M. Ventz, S. Diederich, M. Quinkler, Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J. Clin. Endocrinol. Metab. 97(1), 85\u201392 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"4260_CR106","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2478\/enr-2022-0022","volume":"56","author":"M Yazidi","year":"2022","unstructured":"M. Yazidi, C. Danguir, D. Maamer, I. Oueslati, K. Khiari, M. Elleuch et al., Impact of hydrocortisone replacement on bone mineral density and bone turnover markers in patients with primary adrenal insufficiency. Endocr. Regul. 56(3), 209\u2013215 (2022).","journal-title":"Endocr. Regul."},{"issue":"4","key":"4260_CR107","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1530\/EJE-15-1096","volume":"174","author":"J Schulz","year":"2016","unstructured":"J. Schulz, K.R. Frey, M.S. Cooper, K. Zopf, M. Ventz, S. Diederich et al., Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. Eur. J. Endocrinol. 174(4), 531\u2013538 (2016).","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"4260_CR108","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.tem.2006.03.009","volume":"17","author":"G Mazziotti","year":"2006","unstructured":"G. Mazziotti, A. Angeli, J.P. Bilezikian, E. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17(4), 144\u2013149 (2006).","journal-title":"Trends Endocrinol. Metab."},{"issue":"2","key":"4260_CR109","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1365-2796.2011.02352.x","volume":"270","author":"S Bj\u00f6rnsdottir","year":"2011","unstructured":"S. Bj\u00f6rnsdottir, M. S\u00e4\u00e4f, S. Bensing, O. K\u00e4mpe, K. Micha\u00eblsson, J.F. Ludvigsson, Risk of hip fracture in Addison\u2019s disease: a population-based cohort study. J. Intern. Med. 270(2), 187\u2013195 (2011).","journal-title":"J. Intern. Med."},{"issue":"3","key":"4260_CR110","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12020-011-9591-x","volume":"41","author":"H Falhammar","year":"2012","unstructured":"H. Falhammar, M. Thor\u00e9n, Clinical outcomes in the management of congenital adrenal hyperplasia. Endocrine 41(3), 355\u2013373 (2012).","journal-title":"Endocrine"},{"issue":"12","key":"4260_CR111","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1210\/jc.2007-0744","volume":"92","author":"H Falhammar","year":"2007","unstructured":"H. Falhammar, H. Filipsson, G. Holmdahl, P.O. Janson, A. Nordenskj\u00f6ld, K. Hagenfeldt et al., Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 92(12), 4643\u20134649 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"4260_CR112","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1210\/jc.2009-2616","volume":"95","author":"K Muthusamy","year":"2010","unstructured":"K. Muthusamy, M.B. Elamin, G. Smushkin, M.H. Murad, J.F. Lampropulos, K.B. Elamin et al., Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. J. Clin. Endocrinol. Metab. 95(9), 4161\u20134172 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"4260_CR113","first-page":"1511","volume":"86","author":"JB Quintos","year":"2001","unstructured":"J.B. Quintos, M.G. Vogiatzi, M.D. Harbison, M.I. New, Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 86(4), 1511\u20131517 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"4260_CR114","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1210\/jc.2005-2823","volume":"91","author":"M Sciannamblo","year":"2006","unstructured":"M. Sciannamblo, G. Russo, D. Cuccato, G. Chiumello, S. Mora, Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 91(11), 4453\u20134458 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4260_CR115","doi-asserted-by":"publisher","first-page":"1456679","DOI":"10.3389\/fped.2024.1456679","volume":"12","author":"R Navardauskaite","year":"2024","unstructured":"R. Navardauskaite, A. Vanckaviciene, R. Verkauskiene, Bone mineral density determinants in adolescents and young adults with congenital adrenal hyperplasia. Front. Pediatr. 12, 1456679 (2024).","journal-title":"Front. Pediatr."},{"issue":"1-2","key":"4260_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000515833","volume":"94","author":"TM Espinosa Reyes","year":"2021","unstructured":"T.M. Espinosa Reyes, G. Leyva Gonz\u00e1lez, E. Dom\u00ednguez Alonso, H. Falhammar, Bone mass in young patients with congenital adrenal hyperplasia due to 21-Hydroxylase deficiency. Horm. Res. Paediatr. 94(1-2), 1\u20138 (2021).","journal-title":"Horm. Res. Paediatr."},{"key":"4260_CR117","doi-asserted-by":"publisher","first-page":"105734","DOI":"10.1016\/j.jsbmb.2020.105734","volume":"204","author":"MK Auer","year":"2020","unstructured":"M.K. Auer, L. Paizoni, L.C. Hofbauer, M. Rauner, Y. Chen, H. Schmidt et al., Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency. J. Steroid Biochem. Mol. Biol. 204, 105734 (2020).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"3","key":"4260_CR118","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/cen.12507","volume":"82","author":"D El-Maouche","year":"2015","unstructured":"D. El-Maouche, S. Collier, M. Prasad, J.C. Reynolds, D.P. Merke, Cortical bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin. Endocrinol. 82(3), 330\u2013337 (2015).","journal-title":"Clin. Endocrinol."},{"issue":"5","key":"4260_CR119","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00198-019-05268-0","volume":"31","author":"LL Iervolino","year":"2020","unstructured":"L.L. Iervolino, B. Ferraz-de-Souza, R.M. Martin, F.C. Costa, M.C. Miranda, B.B. Mendon\u00e7a et al., Real-world impact of glucocorticoid replacement therapy on bone mineral density: retrospective experience of a large single-center CAH cohort spanning 24 years. Osteoporos. Int. 31(5), 905\u2013912 (2020).","journal-title":"Osteoporos. Int."},{"issue":"3","key":"4260_CR120","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/EJE-12-0865","volume":"168","author":"H Falhammar","year":"2013","unstructured":"H. Falhammar, H. Filipsson Nystr\u00f6m, A. Wedell, K. Brismar, M. Thor\u00e9n, Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia. Eur. J. Endocrinol. 168(3), 331\u2013341 (2013).","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"4260_CR121","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1046\/j.1365-2265.1996.00851.x","volume":"45","author":"CY Guo","year":"1996","unstructured":"C.Y. Guo, A.P. Weetman, R. Eastell, Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia. Clin. Endocrinol. 45(5), 535\u2013541 (1996).","journal-title":"Clin. Endocrinol."},{"key":"4260_CR122","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3389\/fendo.2020.00493","volume":"11","author":"S Rangaswamaiah","year":"2020","unstructured":"S. Rangaswamaiah, V. Gangathimmaiah, A. Nordenstrom, H. Falhammar, Bone mineral density in adults with congenital adrenal hyperplasia: a systematic review and meta-analysis. Front. Endocrinol. 11, 493 (2020).","journal-title":"Front. Endocrinol."},{"issue":"6","key":"4260_CR123","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1530\/EJE-07-0887","volume":"158","author":"Z Chakhtoura","year":"2008","unstructured":"Z. Chakhtoura, A. Bachelot, D. Samara-Boustani, J.C. Ruiz, B. Donadille, J. Dulon et al., Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. Eur. J. Endocrinol. 158(6), 879\u2013887 (2008).","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"4260_CR124","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1530\/EJE-16-0104","volume":"175","author":"F Ceccato","year":"2016","unstructured":"F. Ceccato, M. Barbot, N. Albiger, M. Zilio, P. De Toni, G. Luisetto et al., Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur. J. Endocrinol. 175(2), 101\u2013106 (2016).","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"4260_CR125","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00198-021-06097-w","volume":"33","author":"JH Borges","year":"2022","unstructured":"J.H. Borges, D.M. de Oliveira, S.H.V. de Lemos-Marini, B. Geloneze, G. Guerra-J\u00fanior, E.M. Gon\u00e7alves, Normal bone health in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy. Osteoporos. Int. 33(1), 283\u2013291 (2022).","journal-title":"Osteoporos. Int."},{"key":"4260_CR126","doi-asserted-by":"publisher","first-page":"326275","DOI":"10.1186\/1687-9856-2010-326275","volume":"2010","author":"A Bachelot","year":"2010","unstructured":"A. Bachelot, Z. Chakhtoura, D. Samara-Boustani, J. Dulon, P. Touraine, M. Polak, Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency. Int. J. Pediatr. Endocrinol. 2010, 326275 (2010).","journal-title":"Int. J. Pediatr. Endocrinol."},{"issue":"6","key":"4260_CR127","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1210\/js.2019-00136","volume":"3","author":"E Whittle","year":"2019","unstructured":"E. Whittle, H. Falhammar, Glucocorticoid regimens in the treatment of congenital adrenal hyperplasia: a systematic review and meta-analysis. J. Endocr. Soc. 3(6), 1227\u20131245 (2019).","journal-title":"J. Endocr. Soc."},{"key":"4260_CR128","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1210\/jc.2009-0636","volume":"94","author":"L Frisen","year":"2009","unstructured":"L. Frisen, A. Nordenstrom, H. Falhammar, H. Filipsson, G. Holmdahl, P. Janson et al., Gender role behavior, sexuality, and psychosocial adaptation in women with congenital adrenal hyperplasia due to CYP21A2 deficiency. J. Clin. Endocrinol. Metab. 94, 3432\u20133439 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"4260_CR129","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1530\/EC-18-0031","volume":"7","author":"H Falhammar","year":"2018","unstructured":"H. Falhammar, H. Claahsen-van der Grinten, N. Reisch, J. Slowikowska-Hilczer, A. Nordenstr\u00f6m, R. Roehle et al., Health status in 1040 adults with disorders of sex development (DSD): a European multicenter study. Endocr. Connect. 7(3), 466\u2013478 (2018).","journal-title":"Endocr. Connect."},{"issue":"5","key":"4260_CR130","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/cen.14391","volume":"94","author":"Y Gao","year":"2021","unstructured":"Y. Gao, O. Wang, W. Guan, X. Wu, J. Mao, X. Wang et al., Bone mineral density and trabecular bone score in patients with 21-hydroxylase deficiency after glucocorticoid treatment. Clin. Endocrinol. 94(5), 765\u2013773 (2021).","journal-title":"Clin. Endocrinol."},{"issue":"5","key":"4260_CR131","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00223-023-01132-w","volume":"113","author":"X Sun","year":"2023","unstructured":"X. Sun, Y. Wu, L. Lu, W. Xia, L. Zhang, S. Chen et al., Bone microarchitecture and volumetric mineral density assessed by HR-pQCT in patients with 21- and 17\u03b1-Hydroxylase deficiency. Calcif. Tissue Int. 113(5), 515\u2013525 (2023).","journal-title":"Calcif. Tissue Int."},{"issue":"11","key":"4260_CR132","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1210\/jc.2018-01865","volume":"103","author":"PW Speiser","year":"2018","unstructured":"P.W. Speiser, W. Arlt, R.J. Auchus, L.S. Baskin, G.S. Conway, D.P. Merke et al., Congenital adrenal hyperplasia due to steroid 21-Hydroxylase deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 103(11), 4043\u20134088 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"4260_CR133","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s12020-023-03330-w","volume":"80","author":"B Righi","year":"2023","unstructured":"B. Righi, S.R. Ali, J. Bryce, J.W. Tomlinson, W. Bonfig, F. Baronio et al., Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia. Endocrine 80(3), 630\u2013638 (2023).","journal-title":"Endocrine"},{"issue":"6","key":"4260_CR134","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2404656","volume":"391","author":"RJ Auchus","year":"2024","unstructured":"R.J. Auchus, O. Hamidi, R. Pivonello, I. Bancos, G. Russo, S.F. Witchel et al., Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia. N. Engl. J. Med. 391(6), 504\u2013514 (2024).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"4260_CR135","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1210\/er.2018-00126","volume":"40","author":"R Bouillon","year":"2019","unstructured":"R. Bouillon, C. Marcocci, G. Carmeliet, D. Bikle, J.H. White, B. Dawson-Hughes et al., Skeletal and extraskeletal actions of Vitamin D: current evidence and outstanding questions. Endocr. Rev. 40(4), 1109\u20131151 (2019).","journal-title":"Endocr. Rev."},{"issue":"3","key":"4260_CR136","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s12020-024-03784-6","volume":"85","author":"L di Filippo","year":"2024","unstructured":"L. di Filippo, J.P. Bilezikian, E. Canalis, U. Terenzi, A. Giustina, New insights into the vitamin D\/PTH axis in endocrine-driven metabolic bone diseases. Endocrine 85(3), 1007\u20131019 (2024).","journal-title":"Endocrine"},{"issue":"5","key":"4260_CR137","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1210\/endrev\/bnae009","volume":"45","author":"A Giustina","year":"2024","unstructured":"A. Giustina, J.P. Bilezikian, R.A. Adler, G. Banfi, D.D. Bikle, N.C. Binkley et al., Consensus statement on Vitamin D status assessment and supplementation: whys, whens, and hows. Endocr. Rev. 45(5), 625\u2013654 (2024).","journal-title":"Endocr. Rev."},{"key":"4260_CR138","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/CE.S172820","volume":"14","author":"AD Taylor","year":"2019","unstructured":"A.D. Taylor, K.G. Saag, Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy. Core Evid. 14, 41\u201350 (2019).","journal-title":"Core Evid."},{"issue":"6","key":"4260_CR139","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/joim.20017","volume":"296","author":"CC Mok","year":"2024","unstructured":"C.C. Mok, K.L. Chan, S.M. Tse, S.P.L. Chen, K.C.B. Tan, W.H. Ma, Romosozumab versus denosumab in long-term users of glucocorticoids: a pilot randomized controlled trial. J. Intern. Med. 296(6), 481\u2013494 (2024).","journal-title":"J. Intern. Med."},{"issue":"9","key":"4260_CR140","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00198-024-07139-9","volume":"35","author":"S Kumar","year":"2024","unstructured":"S. Kumar, M.L. Gild, M.M. McDonald, A.S. Kim, R.J. Clifton-Bligh, C.M. Girgis, A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis. Osteoporos. Int. 35(9), 1669\u20131675 (2024).","journal-title":"Osteoporos. Int."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04260-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04260-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04260-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:20:48Z","timestamp":1757182848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04260-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":140,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["4260"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04260-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A.G. serves as a consultant for Abiogen. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}